» Articles » PMID: 35772828

Impact of COPD and Asthma on In-hospital Mortality and Management of Patients with Heart Failure in England and Wales: an Observational Analysis

Overview
Journal BMJ Open
Specialty General Medicine
Date 2022 Jun 30
PMID 35772828
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate the association between having concomitant chronic obstructive pulmonary disease (COPD) or asthma, and in-patient mortality and post-discharge management among patients hospitalised for acute heart failure (HF).

Setting: Data were obtained from patients enrolled in the National Heart Failure Audit.

Participants: 217 329 patients hospitalised for HF in England-Wales between March 2012 and 2018.

Outcomes: In-hospital mortality, referrals to cardiology follow-up and prescriptions for HF medications were compared between patients with comorbid COPD (COPD-HF) or asthma (asthma-HF) versus HF-alone using mixed-effects logistic regression.

Results: Patients with COPD-HF were more likely to die during hospitalisation, and those with asthma-HF had a reduced likelihood of death, compared with patients who had HF-alone ((adjusted)OR, 95% CI: 1.10, 1.06 to 1.14 and OR, 95% CI: 0.84, 0.79 to 0.88). In patients who survived to discharge, referral to HF follow-up services differed between groups: patients with COPD-HF had reduced odds of cardiology follow-up (OR, 95% CI 0.79, 0.77 to 0.81), while cardiology referral odds for asthma-HF were similar to HF-alone. Overall, proportions of HF medication prescriptions at discharge were low for both COPD-HF and asthma-HF groups, particularly prescriptions for beta-blockers.

Conclusions: In this nationwide analysis, we showed that COPD and asthma significantly impact the clinical course in patients hospitalised for HF. COPD is associated with higher in-patient mortality and lower cardiology referral odds, while COPD and asthma are both associated with lower use of prognostic HF therapies on discharge. These data highlight therapeutic gaps and a need for better integration of cardiopulmonary services to improve healthcare provision for patients with HF and coexisting respiratory disease.

Citing Articles

Higher Vitamin E Intake Reduces Risk of All-Cause Mortality and Chronic Lower Respiratory Disease Mortality in Chronic Obstructive Pulmonary Disease: NHANES (2008-2018).

Tian M, Li W, He X, He Q, Huang Q, Deng Z Int J Chron Obstruct Pulmon Dis. 2024; 19:1865-1878.

PMID: 39185395 PMC: 11345014. DOI: 10.2147/COPD.S468213.


A Research Agenda to Improve Outcomes in Patients with Chronic Obstructive Pulmonary Disease and Cardiovascular Disease: An Official American Thoracic Society Research Statement.

Myers L, Quint J, Hawkins N, Putcha N, Hamilton A, Lindenauer P Am J Respir Crit Care Med. 2024; 210(6):715-729.

PMID: 39133888 PMC: 11418885. DOI: 10.1164/rccm.202407-1320ST.

References
1.
Shaw S, Williams S . Should beta-blockade continue to be withheld from patients with chronic heart failure and asthma?. Eur Heart J. 2009; 30(10):1287. DOI: 10.1093/eurheartj/ehp146. View

2.
Hayhoe B, Kim D, Aylin P, Majeed F, Cowie M, Bottle A . Adherence to guidelines in management of symptoms suggestive of heart failure in primary care. Heart. 2018; 105(9):678-685. DOI: 10.1136/heartjnl-2018-313971. View

3.
Camargo C, Barr R, Chen R, Speizer F . Prospective study of inhaled corticosteroid use, cardiovascular mortality, and all-cause mortality in asthmatic women. Chest. 2008; 134(3):546-551. PMC: 2643337. DOI: 10.1378/chest.07-3126. View

4.
Canepa M, Straburzynska-Migaj E, Drozdz J, Fernandez-Vivancos C, Garcia Pinilla J, Nyolczas N . Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry. Eur J Heart Fail. 2017; 20(1):100-110. DOI: 10.1002/ejhf.964. View

5.
Canepa M, Ameri P, Lainscak M . Chronic obstructive pulmonary disease and comorbidities in heart failure: the next frontier of sodium-glucose co-transporter 2 inhibitors?. Eur J Heart Fail. 2021; 23(4):644-647. DOI: 10.1002/ejhf.2109. View